Spebrutinib
Spebrutinib is an orally bioavailable, selective inhibitor of Bruton’s agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity.
| Catalog Number | T2603 |
| Alternative Name(s) | LMK-435 , AVL-292 , CC-292 |
| Research Area | Angiogenesis|||Tyrosine Kinase/Adaptors |
| Molecular Formula | C22H22FN5O3 |
| CAS# | 1202757-89-8 |
| Purity | 97.14% |
| SMILES | COCCOC1=CC=C(NC2=NC=C(F)C(NC3=CC(NC(=O)C=C)=CC=C3)=N2)C=C1 |
| Size | 5 mg |
| Supplier Page | https://www.targetmol.com/compound/Spebrutinib |
| Additional Information | https://www.targetmol.com/datasheet/T2603 |